Related Experiment Video
Updated: Dec 21, 2025

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
Published on: September 15, 2023
[Clinical observation of 6 severe COVID-19 patients treated with plasma exchange or tocilizumab]
Song Luo1, Lijuan Yang2, Chun Wang1
1Department of Neurology, the First Affiliated Hospital of Bengbu Medical College, Bengbu 233004, Anhui Province, China.
Insights
Plasma exchange significantly reduced inflammation and improved outcomes in severe COVID-19 patients. Tocilizumab showed no significant effect on inflammation or patient recovery.
Area of Science:
- Critical Care Medicine
- Infectious Diseases
- Immunology
Background:
- Severe coronavirus disease 2019 (COVID-19) can lead to excessive inflammatory responses.
- Identifying effective treatments for severe COVID-19 is crucial.
Purpose of the Study:
- To compare the clinical efficacy of plasma exchange and tocilizumab in managing severe COVID-19.
- To assess the impact of these treatments on inflammatory markers.
Main Methods:
- A comparative study involving six severe COVID-19 patients.
- Three patients received plasma exchange, and three received tocilizumab.
- Observed effects on inflammatory reactions and clinical parameters.
Main Results:
- Plasma exchange led to significant reductions in C-reactive protein (CRP) and IL-6 levels.
- Patients treated with plasma exchange showed improved lymphocyte counts and prothrombin time.
- Tocilizumab did not significantly decrease inflammation markers or improve clinical outcomes.
Conclusions:
- Plasma exchange appears to be a preferred treatment for severe COVID-19 patients experiencing hyperinflammation.
- Further research is warranted to confirm these findings.
Objective:
To observe the clinical effect of plasma exchange and tocilizumab in treatment of patients with severe coronavirus disease 2019 (COVID-19).
Methods:
Six patients with severe COVID-19 admitted in First Affiliated Hospital of Bengbu Medical College from January 25 to February 25, 2020. Three patients were treated with plasma exchange and three patients were treated with tocilizumab. The effect on excessive inflammatory reaction of plasma exchange and tocilizumab was observed.
Results:
The C-reactive protein (CRP) and IL-6 levels were significantly decreased and the lymphocyte and prothrombin time were improved in 3 patients after treatment with plasma exchange; while inflammation level was not significantly decreased, and lymphocyte and prothrombin time did not improve in 3 patients treated with tocilizumab.
Conclusions:
For severe COVID-19 patients with strong inflammatory reaction, plasma exchange may be preferred.
More Related Videos
Related Concept Videos
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Respiratory Failure-II
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
Blood Transfusion and Agglutination
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
Acute Respiratory Failure-III

